Moving the goalposts while scoring―the dilemma posed by new PET technologies

Rogasch, J; Boellaard, Ronald; Pike, Lucy; Borchmann, Peter; Johnson, Peter; Wolf, Jürgen; Barrington, Sally F.; Kobe, Carsten

doi:10.1007/s00259-021-05403-2

Cited by 13 publications

(11 citation statements)

References 116 publications

(234 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Integrating PSF in reconstructions across PET/CT systems has already been suggested ( 4 ). The present study validates the application of PSF to brain 18 F-FDG PET imaging as a diagnostic thinking efficacy, a confirmation that was previously lacking in the context of AD ( 1 ).…”

Section: Discussionsupporting

confidence: 88%

See 1 more Smart Citation

Effect of Point Spread Function Deconvolution in Reconstruction of Brain 18F-FDG PET Images on the Diagnostic Thinking Efficacy in Alzheimer's Disease

et al. 2021

View full text Add to dashboard Cite

Purpose: This study aims to determine the effect of applying Point Spread Function (PSF) deconvolution, which is known to improve contrast and spatial resolution in brain 18F-FDG PET images, to the diagnostic thinking efficacy in Alzheimer's disease (AD).Methods: We compared Hoffman 3-D brain phantom images reconstructed with or without PSF. The effect of PSF deconvolution on AD diagnostic clinical performance was determined from digital brain 18F-FDG PET images of AD (n = 38) and healthy (n = 35) subjects compared to controls (n = 36). Performances were assessed with SPM at the group level (p < 0.001 for the voxel) and at the individual level by visual interpretation of SPM T-maps (p < 0.005 for the voxel) by the consensual analysis of three experienced raters.Results: A mix of large hypometabolic (1,483cm3, mean value of −867 ± 492 Bq/ml) and intense hypermetabolic (902 cm3, mean value of 1,623 ± 1,242 Bq/ml) areas was observed in the PSF compared to the no PSF phantom images. Significant hypometabolic areas were observed in the AD group compared to the controls, for reconstructions with and without PSF (respectively 23.7 and 26.2 cm3), whereas no significant hypometabolic areas were observed when comparing the group of healthy subjects to the control group. At the individual level, no significant differences in diagnostic performances for discriminating AD were observed visually (sensitivity of 89 and 92% for reconstructions with and without PSF respectively, similar specificity of 74%).Conclusion: Diagnostic thinking efficacy performances for diagnosing AD are similar for 18F-FDG PET images reconstructed with or without PSF.

show abstract

Section: Discussionsupporting

confidence: 88%

“…Particularly, these methods include a resolution modeling or point-spread function (PSF) available on all vendors of clinical PET/CT systems. This PSF allows to correct from the system's depiction of point sources depending on their location in the field of view ( 1 ).…”

Section: Introductionmentioning

confidence: 99%

Effect of Point Spread Function Deconvolution in Reconstruction of Brain 18F-FDG PET Images on the Diagnostic Thinking Efficacy in Alzheimer's Disease

et al. 2021

View full text Add to dashboard Cite

show abstract

“…This was translated into developments and improvements in reconstruction methods and corrections, such as point-spread-function (PSF). The benefits [ 8 ] and challenges [ 9 ] of using these improvements are well described in the literature. Accompanying the computational evolutions were advancements in the fields of scintillation material and detector design.…”

Section: Instrumentation Developmentsmentioning

confidence: 99%

New Radionuclides and Technological Advances in SPECT and PET Scanners

Meulen

Strobel

Lima

2021

Cancers

View full text Add to dashboard Cite

Developments throughout the history of nuclear medicine have involved improvements in both instrumentation and radionuclides, which have been intertwined. Instrumentation developments always occurred during the search to improving devices’ sensitivity and included advances in detector technology (with the introduction of cadmium zinc telluride and digital Positron Emission Tomography—PET-devices with silicon photomultipliers), design (total body PET) and configuration (ring-shaped, Single-Photon Emission Computed Tomography (SPECT), Compton camera). In the field of radionuclide development, we observed the continual changing of clinically used radionuclides, which is sometimes influenced by instrumentation technology but also driven by availability, patient safety and clinical questions. Some areas, such as tumour imaging, have faced challenges when changing radionuclides based on availability, when this produced undesirable clinical findings with the introduction of unclear focal uptakes and unspecific uptakes. On the other end of spectrum, further developments of PET technology have seen a resurgence in its use in nuclear cardiology, with rubidium-82 from strontium-82/rubidium-82 generators being the radionuclide of choice, moving away from SPECT nuclides thallium-201 and technetium-99m. These continuing improvements in both instrumentation and radionuclide development have helped the growth of nuclear medicine and its importance in the ever-evolving range of patient care options.

show abstract

“…This review belongs to a two-This article is part of the Topical Collection on Technology part series of reviews published in EJNMMI addressing the pros and cons of new PET technologies. The complementary review by Julian MM Rogasch et al [1] covers the cons.…”

Section: Introductionmentioning

confidence: 99%